Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Study testing whether adding enzalutamide to standard hormone therapy and radiation improves survival and quality of life for people with high-risk prostate cancer that has not spread beyond the prostate.
Primary Sponsor
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Chairperson
Professor Scott Williams
Professor Paul Nguyen
Trial Contact
enzarad.study@sydney.edu.au
Related Post
17 September, 2026
Meet the TROG Quality Assurance team
TROG UPDATES: 17 September 2026 Our Quality Assurance team
17 September, 2026
TROG trial of new lung cancer radiation therapy approach opens
LATEST NEWS: 17 September 2026 The first Australian site